Skip to main content
NINDSNIMHNICHDNIDCDNEINIDCRNIANIAAANIDANHGRI NCCIHNIDDKNIEHSCCB

Profile Image

Senior Investigator

Marc L. Reitman, M.D., Ph.D.

Diabetes, Endocrinology, and Obesity Branch

Energy Homeostasis Section
Building 10 Room 5-5940
Center Drive
Bethesda MD 20892
Office: 301-496-6442


marc.reitman@nih.gov

Since 2011, Dr. Reitman has been a Senior Investigator and the Branch Chief of the Diabetes, Endocrinology, and Obesity Branch with NIDDK. Prior to this appointment he served as the Director of Clinical Research and Director of Obesity and Metabolic Research for Merck Research Laboratories from 2002 to 2011. He completed his residency in Internal Medicine at Columbia-Presbyterian Hospital in 1986. He earned a M.D., Ph.D. from Washington University in 1983 after graduating with a B.S. in 1977 from Massachusetts Institute of Technology.



Obesity has reached pandemic proportions and treatment is rarely successful for the long term. Dr. Reitman and his lab believe that by elucidating the underlying physiology, novel and effective anti-obesity therapies will be discovered. Effective obesity treatment will also stem the epidemic of type 2 diabetes mellitus. Currently, Dr. Reitman is broadly interested in a mechanistic and translational understanding of diabetes, energy homeostasis, and obesity. His particular interests include studying mouse genetics and pharmacology, using mouse models to understand metabolic rate regulation, body temperature regulation and the role of BRS-3 (bombesin receptor subtype-3), and exploring drug treatments for obesity. One current project involves dissecting the neuroscience of how BRS-3 regulates metabolic rate, body temperature, and blood pressure. Another project explores how to improve the use of mice to evaluate candidate treatments for human obesity. A third interest is the role of brown adipose tissue and uncoupling in mouse and human thermal biology and body weight regulation. By studying the mechanisms involved in energy homeostasis, Dr. Reitman and his lab should gain knowledge that will lead to advancements in the treatment of diabetes and obesity.

Staff Image
  • 1) Carlin JL, Jain S, Gizewski E, Wan TC, Tosh DK, Xiao C, Auchampach JA, Jacobson KA, Gavrilova O, Reitman ML (2017)
  • Hypothermia in mouse is caused by adenosine A1 and A3 receptor agonists and AMP via three distinct mechanisms
  • Neuropharmacology, 114, 101-113
  • 2) Lateef DM, Xiao C, Brychta RJ, Diedrich A, Schnermann J, Reitman ML (2016)
  • Bombesin-like receptor 3 regulates blood pressure and heart rate via a central sympathetic mechanism
  • Am J Physiol Heart Circ Physiol, 310(7), H891-8
  • 3) Xiao C, Reitman ML (2016)
  • Bombesin-Like Receptor 3: Physiology of a Functional Orphan
  • Trends Endocrinol Metab, 27(9), 603-5
  • 4) Abreu-Vieira G, Xiao C, Gavrilova O, Reitman ML (2015)
  • Integration of body temperature into the analysis of energy expenditure in the mouse
  • Mol Metab, 4(6), 461-70
  • 5) Lute B, Jou W, Lateef DM, Goldgof M, Xiao C, Piñol RA, Kravitz AV, Miller NR, Huang YG, Girardet C, Butler AA, Gavrilova O, Reitman ML (2014)
  • Biphasic effect of melanocortin agonists on metabolic rate and body temperature
  • Cell Metab, 20(2), 333-45
View Pubmed Publication